Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Non-Current Debt (2021 - 2023)

Candel Therapeutics' Non-Current Debt history spans 3 years, with the latest figure at $14.3 million for Q3 2023.

  • For Q3 2023, Non-Current Debt fell 28.74% year-over-year to $14.3 million; the TTM value through Sep 2023 reached $14.3 million, down 28.74%, while the annual FY2022 figure was $20.2 million, 3507.5% up from the prior year.
  • Non-Current Debt for Q3 2023 was $14.3 million at Candel Therapeutics, down from $16.7 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $20.2 million in Q4 2022 and bottomed at $560000.0 in Q4 2021.
  • The 3-year median for Non-Current Debt is $19.5 million (2022), against an average of $16.4 million.
  • The largest annual shift saw Non-Current Debt skyrocketed 3507.5% in 2022 before it fell 28.74% in 2023.
  • A 3-year view of Non-Current Debt shows it stood at $560000.0 in 2021, then surged by 3507.5% to $20.2 million in 2022, then dropped by 29.02% to $14.3 million in 2023.
  • Per Business Quant, the three most recent readings for CADL's Non-Current Debt are $14.3 million (Q3 2023), $16.7 million (Q2 2023), and $19.0 million (Q1 2023).